News

In this podcast episode, partner Holly Bunting discusses the evolving regulatory landscape for home equity investment (HEI) contracts, which have gained popularity as an alternative to traditional home equity lines of credit amid rising interest rates.

In 2025, the U.S. radiopharmaceutical market is expected to see continued growth, driven by aging populations, advancements in theranostics, an increased demand for targeted cancer treatments and an expansion of applications beyond oncology.

President Trump announced new tariffs on April 2, 2025, which he referred to as “reciprocal tariffs,” on almost all imports into the United States. The tariff package will be rolled out in two phases. Tariffs of 10 percent were imposed on all countries as of April 5.

Le 26 mars 2025, Dale Nally, le ministre responsable des services et de la réduction du fardeau administratif en Alberta, a présenté le projet de loi 48, aussi connu sous le nom iGaming Alberta Act (le « projet de loi 48 ») à l’Assemblée législative....

I’ve been in the retirement plan business for 26 years and I’ve been through a few recessions in that time. There was the dot-bomb implosion, added by 9/11. Let us not forget when our entire financial system was on the verge of collapse in 2008....

On April 2, 2025, President Trump signed an executive order imposing reciprocal tariffs on most trading partners.

In honour of the International Association of Privacy Professionals (IAPP) London 2025 conference , we hosted a webinar on European privacy litigation. This post summarises some of the key UK privacy cases we covered in that webinar.

On April 3, 2025, the Department of Labor (“DOL”) issued Field Assistance Bulletin 2025-02 (the “Bulletin”), which provides guidance related to certain modifications made by the SECURE 2.0 Act of 2022 (“SECURE 2.0”) to the annual funding notice (“AFN”) requirements applicable to defined benefit p

Stemming from concerns raised during the COVID pandemic, the Ohio General Assembly recently passed House Bill 236, dubbed the “Never Alone Act,” (“Act”) which became effective March 20, 2025.

On March 31, 2025, in the U.S. District Court for the Eastern District of Texas vacated the Food and Drug Administration’s (FDA) final rule, in which FDA attempted to assert regulatory authority over laboratory-developed tests (LDT) as “devices” under the Food, Drug, and Cosmetic Act (FDCA).

Pages